Key Highlights

● Thermo Fisher rose alongside a broad rally in life-science tools stocks including Charles River and Danaher.

● The move stood apart from a weak health care sector, where Merck and Bristol-Myers Squibb fell.

● Vaccine stocks were a bright spot, with Vaxcyte soaring on strong trial data.

Thermo Fisher Scientific rose on Monday, Oct. 5, as life-science tools stocks rallied together and stood apart from a weak session for big pharmaceutical names.

Tools stocks move as a pack

Thermo Fisher Scientific (NYSE:TMO) climbed on Monday, according to market data, finishing among the gainers in the S&P 500.

Thermo Fisher rode a rally across life-science tools. Charles River Laboratories (NYSE:CRL) climbed sharply to a 52-week high of $303.33 and was the second-best performer in the S&P 500. Danaher (NYSE:DHR) rose, and Illumina (NASDAQ:ILMN) jumped. Tempus AI (NASDAQ:TEM), a smaller name tied to health data and diagnostics, also rallied.

What Thermo Fisher sells

Thermo Fisher is the largest company in the life-science tools industry. It supplies the instruments, lab equipment, chemicals and consumables that drugmakers, biotech firms, universities, hospitals and diagnostic labs use every day. It also offers outsourced services that help pharmaceutical companies develop and manufacture medicines.

Because so much of its Business depends on research and drug-development budgets, investors often trade Thermo Fisher and its peers together as a group. When sentiment toward that spending improves, the whole basket tends to rise.

Bucking a weak health care tape

The strength in tools stood out because the rest of health care struggled. The sector was the weakest in the S&P 500 at midday and posted a modest decline at the close.

Merck (NYSE:MRK) was the worst stock in the Dow. Bristol-Myers Squibb (NYSE:BMY) slid after Leerink Partners analyst David Risinger downgraded it to Market Perform, citing pipeline risks. "We changed our Investment thesis after conducting more detailed assessments of key pipeline candidates reading out over the next several months," Risinger said. Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) also fell.

Vaccines were a bright spot. Vaxcyte (NASDAQ:PCVX) soared on late-stage trial data for its pneumococcal vaccine, and Moderna (NASDAQ:MRNA) rallied ahead of joining the Nasdaq-100.

Records for the Nasdaq

The broader market finished higher. The Nasdaq Composite rose 286.45 points to a record close of 27,477.31, and the Nasdaq-100 set a record at 31,076.44. The S&P 500 gained 51.23 points to 7,773.95, just shy of its summer record, and the Dow Jones Industrial Average added 90.94 points to 51,267.90.

That came even as the 10-year Treasury Yield rose to its highest close since 2002. The ISM services survey showed prices paid at the highest since July 2022, keeping Inflation in focus. Friday's weak jobs report, with just 29,000 positions added in September, cut the odds of another Fed rate hike in October to roughly one in four or less, down from better than even a week earlier.

Daniela Hathorn of Capital.com said: "growth stocks are rallying because Fed expectations have softened, while the Risk-Free Rate against which those valuations are judged remains exceptionally high."

Oil eased too, with Brent settling at $100.32 a barrel after G7 nations agreed to release 100 million barrels of crude and diesel from emergency reserves.

What to watch

For Thermo Fisher, the next major checkpoint is its quarterly Earnings report, where investors will look for signs of Demand from pharmaceutical, biotech and academic customers. Results from peers will also be watched as a read on the whole tools group.

For the wider market, minutes of the Fed's September meeting are due on Wednesday, Oct. 7, at 2 p.m. ET. PepsiCo reports Thursday, Delta Air Lines Friday, and bank earnings start on Oct. 13. The Fed's next policy meeting is Oct. 27–28.